United States · Resolution · HRES
H.Res. 309 (118th)
Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
Introduced
19 April 2023
Last action
—
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
—
Subjects
Discovery layer
Source updated
24 July 2024
Summary
This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's authority.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 19 April 2023
Introduced in House (PDF)
Introduced in House · EN · 19 April 2023
Introduced in House
summary · EN · 19 April 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/house-resolution/309
- Open data entity: https://api.congress.gov/v3/bill/118/hres/309